Osimertinib

Osimertinib with Chemotherapy in EGFR-Mutated NSCLC | NEJM

Continued use of osimertinib reduces CNS metastasis in EGFR mutant lung cancer

ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial

European Society for Medical Oncology (ESMO)

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated a...

Osimertinib + ipilimumab in EGFR-mutated NSCLC

Osimertinib for EGFR-mutant lung cancer

Adjuvant Osimertinib and Advanced EGFR-Mutated NSCLC | NEJM

Osimertinib and chemotherapy in EGFR+ lung cancer with TP53 and RB1 alterations

Resistance to Osimertinib in EGFR-Mutated NSCLC

Osimertinib’s Role in EGFR+ Metastatic Lung Cancer

Osimertinib resistance in non-small cell lung cancer: Pathways and potential solutions

AJE Video Bytes

Dr. Goldberg on Options After Developing Resistance to Osimertinib for NSCLC

Dr. Ramalingam on the Role of Osimertinib in eGFR T790M-Positive Advanced NSCLC

Osimertinib and the FLAURA Trial

GRACE - Global Resource for Advancing Cancer Education

Osimertinib for Treatment of EGFR+ Lung Cancer

Targeted Oncology

Osimertinib in EGFR-Positive NSCLC With Brain Metastases

Dr. Gold on the Future of Osimertinib in Lung Cancer

Role of Adjuvant Osimertinib in Early Stage NSCLC

Post-Osimertinib Treatment Options for EGFR+ NSCLC - Targeted Therapies in Lung Cancer 2023

GRACE - Global Resource for Advancing Cancer Education

The ADAURA study/ Osimertinib: How Cheerleaders Fail Patients

Vinay Prasad MD MPH